Company: Agile Therapeutics
Based: Princeton, NJ
Investors: Investor Growth Capital, Care Capital, ProQuest Investments, Kaiser Permanente Ventures and Novitas Capital
Scoop: After a three-year dry spell, Agile Therapeutics entered the VC fray with a $45 million Series B preferred stock financing with three new investing firms. "The general conditions of the market don't help any company raise money, and we're one of the few that's done a significant raise from external investors," former Agile CEO Thomas Rossi told FierceBiotech at the time.
Agile is using the funding to finish a Phase III clinical trial of its weekly contraceptive patch AG200-15, a potential competitor to the market's only approved contraceptive patch, Johnson & Johnson's Ortho Evra. The company finished enrollment for its Phase III trial in October.